Yeah if that's all they did that's fine. They didn't. They drew conclusions not based on the data available (we feel it was because of remestemcell).
I understand what case reports are, and I understand what conclusions you can draw from them. From this one you can draw even less than normal.
From the data presented the kids were already improving, the trend of the BNP and CRP and whatever they want to look at was firmly in place.
You can't say from the data that it was likely remestemcell that did this. But they're comfortable saying that.
My issue has never been with the fact it's a case report. I've mentioned that a number of times. It's that even as far as case reports go it is not convincing and you should not draw the conclusion that they did.
Do with it what you will.
Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-165
-
- There are more pages in this discussion • 259 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |